360 related articles for article (PubMed ID: 27738953)
1. The Impact of Inspiratory Flow Rate on Drug Delivery to the Lungs with Dry Powder Inhalers.
Weers J; Clark A
Pharm Res; 2017 Mar; 34(3):507-528. PubMed ID: 27738953
[TBL] [Abstract][Full Text] [Related]
2. The clinical relevance of dry powder inhaler performance for drug delivery.
Demoly P; Hagedoorn P; de Boer AH; Frijlink HW
Respir Med; 2014 Aug; 108(8):1195-203. PubMed ID: 24929253
[TBL] [Abstract][Full Text] [Related]
3. In Vitro Dosing Performance of the ELLIPTA® Dry Powder Inhaler Using Asthma and COPD Patient Inhalation Profiles Replicated with the Electronic Lung (eLung™).
Hamilton M; Leggett R; Pang C; Charles S; Gillett B; Prime D
J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):498-506. PubMed ID: 26372465
[TBL] [Abstract][Full Text] [Related]
4. Effect of Disease Severity in Asthma and Chronic Obstructive Pulmonary Disease on Inhaler-Specific Inhalation Profiles Through the ELLIPTA® Dry Powder Inhaler.
Prime D; de Backer W; Hamilton M; Cahn A; Preece A; Kelleher D; Baines A; Moore A; Brealey N; Moynihan J
J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):486-97. PubMed ID: 26372467
[TBL] [Abstract][Full Text] [Related]
5. A review of co-milling techniques for the production of high dose dry powder inhaler formulation.
Lau M; Young PM; Traini D
Drug Dev Ind Pharm; 2017 Aug; 43(8):1229-1238. PubMed ID: 28367654
[TBL] [Abstract][Full Text] [Related]
6. The ELLIPTA® Dry Powder Inhaler: Design, Functionality, In Vitro Dosing Performance and Critical Task Compliance by Patients and Caregivers.
Grant AC; Walker R; Hamilton M; Garrill K
J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):474-85. PubMed ID: 26372466
[TBL] [Abstract][Full Text] [Related]
7. Dry powder inhalers in COPD, lung inflammation and pulmonary infections.
Muralidharan P; Hayes D; Mansour HM
Expert Opin Drug Deliv; 2015 Jun; 12(6):947-62. PubMed ID: 25388926
[TBL] [Abstract][Full Text] [Related]
8. Do all dry powder inhalers show the same pharmaceutical performance?
Taylor A; Gustafsson P
Int J Clin Pract Suppl; 2005 Dec; (149):7-12. PubMed ID: 16279997
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and pharmacodynamics of fluticasone propionate and salmeterol delivered as a combination dry powder from a capsule-based inhaler and a multidose inhaler in asthma and COPD patients.
Daley-Yates PT; Mehta R; Chan RH; Despa SX; Louey MD
J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):279-89. PubMed ID: 24074143
[TBL] [Abstract][Full Text] [Related]
10. [Respimat®, first Soft Mist™ inhaler: new perspectives in the management of COPD].
Henriet AC; Marchand-Adam S; Mankikian J; Diot P
Rev Mal Respir; 2010 Dec; 27(10):1141-9. PubMed ID: 21163393
[TBL] [Abstract][Full Text] [Related]
11. The inhalation characteristics of patients when they use different dry powder inhalers.
Azouz W; Chetcuti P; Hosker HS; Saralaya D; Stephenson J; Chrystyn H
J Aerosol Med Pulm Drug Deliv; 2015 Feb; 28(1):35-42. PubMed ID: 24815999
[TBL] [Abstract][Full Text] [Related]
12. FIDEPOC: Consensus on Inspiratory Flow and Lung Deposition as Key Decision Factors in COPD Inhaled Therapy.
González-Torralba F; Baloira A; Abad A; Fuster A; García-Rivero JL; García-Sidro P; Márquez-Martín E; Palop M; Soler N; Velasco JL
Int J Chron Obstruct Pulmon Dis; 2022; 17():1005-1015. PubMed ID: 35547784
[TBL] [Abstract][Full Text] [Related]
13. The Ellipta
Jones TL; Neville DM; Chauhan AJ
Ther Deliv; 2018 Feb; 9(3):169-176. PubMed ID: 29424288
[TBL] [Abstract][Full Text] [Related]
14. [Easyhaler--ideal dry powder inhaler].
Andrzej E; Małgorzata BE
Pol Merkur Lekarski; 2010 Apr; 28(166):307-10. PubMed ID: 20491343
[TBL] [Abstract][Full Text] [Related]
15. Optimising Inhaled Pharmacotherapy for Elderly Patients with Chronic Obstructive Pulmonary Disease: The Importance of Delivery Devices.
Lavorini F; Mannini C; Chellini E; Fontana GA
Drugs Aging; 2016 Jul; 33(7):461-73. PubMed ID: 27216613
[TBL] [Abstract][Full Text] [Related]
16. Dry powder inhalers: an overview.
Atkins PJ
Respir Care; 2005 Oct; 50(10):1304-12; discussion 1312. PubMed ID: 16185366
[TBL] [Abstract][Full Text] [Related]
17. [Ambulatory criteria of dry powder inhaler selection based on peak inspiratory flow recordings].
Droszcz W; Droscez P
Pneumonol Alergol Pol; 2002; 70(9-10):490-5. PubMed ID: 12710102
[TBL] [Abstract][Full Text] [Related]
18. Total emitted dose of salbutamol sulphate at different inhalation flows and inhalation volumes through different types of dry powder inhalers.
Boshra MS; Almeldien AG; Salah Eldin R; Elberry AA; Abdelwahab NS; Nabil Salem M; Rabea H; Abdelrahim MEA
Exp Lung Res; 2018; 44(4-5):211-216. PubMed ID: 30346848
[TBL] [Abstract][Full Text] [Related]
19. Design of dry powder inhalers to improve patient outcomes: it's not just about the device.
Weers JG
Expert Opin Drug Deliv; 2024 Mar; 21(3):365-380. PubMed ID: 38630860
[TBL] [Abstract][Full Text] [Related]
20. Comparing clinical features of the nebulizer, metered-dose inhaler, and dry powder inhaler.
Geller DE
Respir Care; 2005 Oct; 50(10):1313-21; discussion 1321-2. PubMed ID: 16185367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]